Quantcast

Latest Sirolimus Stories

2009-12-07 14:51:09

After suffering heart attacks, patients often receive stents designed to hold their arteries open. Some of these stents release drugs that are meant to halt tissue growth in arteries, but can have life-threatening side effects such as increasing the likelihood of blood clots and heart attacks. Now a team of researchers in the MIT-Harvard Division of Health Sciences and Technology has developed a computer model that explains why those drugs (which include rapamycin and its analogs as well as...

2009-12-06 17:35:00

A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by Dana-Farber Cancer Institute investigators at the American Society of Hematology's (ASH) annual meeting on Sunday, Dec. 6 (Abstract 48, Ernest N. Morial Convention Center, Room 243-245, 5:45 pm CT). The...

2009-12-01 10:32:00

FORT LAUDERDALE, Fla., Dec. 1 /PRNewswire/ -- OrbusNeich today announced the initiation of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent). A prospective, randomized, multicenter study, REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt) will enroll 180 patients at up to 20 sites in Asia, Australia, Europe and South America. The primary objective is to demonstrate the safety and...

2009-11-16 08:00:00

JAMAICA PLAIN, Mass., Nov. 16 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. announced it will give a presentation today at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics, "Palomid 529, a dual mTor1/2 inhibitor, efficiently penetrates the blood brain barrier and may be an attractive agent for treatment of glioblastoma" by Dr. Olaf van Tellingen, Ph.D. of The Netherlands Cancer Institute, Amsterdam, The Netherlands. (Logo:...

2009-11-01 06:19:03

Treatment reduces risk, but nearly half of patients stop treatment due to side effects Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA. "In spite of the life-saving nature of organ transplantation, the need for transplant recipients to continue treatment with drugs that suppress the...

2009-10-27 09:51:12

Johns Hopkins scientists report having used a commercially available drug to successfully "rescue" animal brain cells that they had intentionally damaged by manipulating a newly discovered gene that links susceptibility genes for schizophrenia and autism. The rescue, described as "surprisingly complete" by the researchers, was accomplished with rapamycin, a drug known to act on a protein called mTOR whose role involves the production of other proteins. The idea to test this drug's...

2009-10-21 06:30:00

UNION CITY, Calif., Oct. 21 /PRNewswire/ -- MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced that it has received Fast Track designation from the United States Food and Drug Administration (FDA) for Perceiva, the company's proprietary ocular sirolimus product, for the treatment of diabetic macular edema (DME). MacuSight is currently advancing Perceiva in a broad Phase 2 clinical program across multiple large...

2009-10-19 17:30:00

SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive. Votrient is intended for people with advanced renal cell carcinoma, a type of kidney cancer...

2009-10-16 08:59:00

NEW YORK, Oct. 16 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Competitor Analysis: PI3K-AKT-mTOR Inhibitors http://www.reportlinker.com/p0154665/Reportlinker-Adds-Competitor-Analysis-PI3K-AKT-mTOR-Inhibitors.html Product description The present Competitive Intelligence Report about PI3K-AKT-mTOR Inhibitors provides a competitor evaluation in the field of novel molecular entities inhibiting members of...

2009-10-02 08:26:29

Diet boosts mitochondrial function, has implications for humans Flies fed an "anti-Atkins" low protein diet live longer because their mitochondria function better. The research, done at the Buck Institute for Age Research, shows that the molecular mechanisms responsible for the lifespan extension in the flies have important implications for human aging and diseases such as obesity, diabetes and cancer. The findings, which appear in the October 2 edition of Cell, also provide a new level of...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'